Lexicon Pharmaceuticals, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless stated otherwise.
Business context
Lexicon is a clinical-stage biopharmaceutical company with no revenue from pharmaceutical product sales. Its principal programs were telotristat etiprate for carcinoid syndrome and sotagliflozin for type 1 diabetes. The company reported that it would not continue developing sotagliflozin for type 2 diabetes unless it obtained a collaboration partner.
Financial results and liquidity
| Metric | 2014 | 2013 | Change or context |
|---|---|---|---|
| Revenue | $22.9 | $2.2 | Up 929%; primarily reflected the Ipsen license agreement. Ipsen represented 94% of 2014 revenue. |
| Research and development expense | $89.3 | $89.7 | Broadly unchanged year over year. |
| General and administrative expense | $19.4 | $17.1 | Up 13%, including higher severance and commercialization preparation costs. |
| Operating loss | $100.4 | $102.4 | 2014 included a $13.1 building impairment and a $1.4 increase in the Symphony Icon liability. |
| Net loss | $100.3 | $104.1 | Net loss per share was $0.19 versus $0.20. |
| Cash, cash equivalents and short-term investments | $339.3 | $129.1 | At December 31; includes $0.4 of restricted investments. |
| Working capital | $324.0 | $115.3 | At December 31. |
| Debt principal | $107.7 | — | $87.5 of 5.25% convertible notes due 2021 and $20.2 mortgage debt; the mortgage was classified current because management planned repayment on sale of the property. |
Cash used in operating activities was $75.6 million, compared with $91.1 million in 2013. Investing activities used $108.4 million, principally reflecting net investment purchases. Financing activities provided $283.8 million, including $202.3 million of net common-stock proceeds and $82.4 million of net debt proceeds. No meaningful product gross margin was reported; the filing does not provide a product-sales basis for assessing operating margins.
Fourth-quarter 2014 revenue was $21.5 million, operating loss was $3.4 million, and net loss was $2.9 million. The quarter’s revenue was driven by recognition of most of the Ipsen upfront license payment.
Material changes versus prior periods
- The Ipsen agreement generated a $23 million upfront payment; Lexicon recognized $21.2 million for the license in 2014 and recognized the remaining allocated amount over service periods. Revenue increased sharply from 2013, but remained highly concentrated in one partner.
- The company raised approximately $201.9 million net through a November 2014 public offering and private placement, issuing about 204.9 million shares. It also issued $87.5 million principal amount of convertible notes.
- Lexicon recorded a $13.1 million impairment after classifying its Texas buildings and land as held for sale. A proposed $24.5 million sale was terminated in January 2015.
- A workforce reduction of approximately 125 employees, about 50% of staff, was substantially completed by the end of the second quarter. Expected cash restructuring charges were approximately $5.7 million.
Outlook, risks and contingencies
- Management said existing capital resources and expected collaboration revenue would fund currently planned operations for at least 12 months. Planned spending included telotristat Phase 3 work and, for sotagliflozin, three Phase 3 type 1 diabetes trials expected to enroll approximately 2,900 patients, a dose-ranging study, and a younger-adult Phase 2 study.
- Telotristat’s pivotal Phase 3 trial enrolled 135 patients; enrollment was completed in March 2015, after year-end. A companion Phase 3 study was planned for a separate patient population. Approval remained uncertain, including the possibility that regulators could require additional trials.
- Ipsen received exclusive commercialization rights for telotristat outside the United States, Canada and Japan. Lexicon may receive up to approximately $30 million in regulatory and launch milestones, up to €72 million in sales milestones, and tiered royalties in the low-twenties to mid-thirties percentage range. These payments are contingent and not assured.
- The FDA had requested a sotagliflozin cardiovascular risk assessment and required a dose-ranging study. Management cautioned that results could require changes to the planned Phase 3 program or delay approval. Phase 3 efficacy and safety remain unproven.
- Lexicon has a history of losses, with a $1.1 billion accumulated deficit, and expects continued losses and substantial development spending. Future collaboration receipts and milestones are uncertain; additional financing may be needed and could dilute shareholders.
- Other exposures include the notes’ conversion and fundamental-change repurchase terms; contingent payments to Symphony Icon Holdings tied to licensing proceeds; and potential Texas Enterprise Fund repayment of up to approximately $14.2 million if job obligations are not met, before applicable credits.
- Invus and affiliates held approximately 59.8% of outstanding common shares, giving them substantial influence over company matters. The New Jersey lease termination, effective June 2015, was agreed after year-end.
Important facts for investors to verify
- Progress, results and regulatory feedback for the telotristat pivotal and companion Phase 3 studies, including whether the FDA will accept one pivotal trial.
- Funding, enrollment, dose selection and safety findings for the sotagliflozin type 1 diabetes program, including the cardiovascular risk assessment.
- Cash burn and remaining liquidity relative to planned trial and commercialization spending; the filing’s 12-month runway statement is management’s estimate.
- Actual timing and amounts of Ipsen milestones, royalties and supply economics, as well as related Symphony Icon contingent payments.
- Effects of the large 2014 equity issuance and convertible-note terms on dilution, debt service and potential future financing needs.
- Outcome of plans for the Texas facilities and the resulting mortgage repayment, lease costs and any Texas Enterprise Fund job-related obligations.